Publication: Ethical issues in haemophilia
Issued Date
2006-07-01
Resource Type
ISSN
13652516
13518216
13518216
Other identifier(s)
2-s2.0-33646132057
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Haemophilia. Vol.12, No.SUPPL. 3 (2006), 30-35
Suggested Citation
Donna DiMichele, A. Chuansumrit, A. J. London, A. R. Thompson, C. G. Cooper, R. M. Killian, L. F. Ross, D. Lillicrap, J. Kimmelman Ethical issues in haemophilia. Haemophilia. Vol.12, No.SUPPL. 3 (2006), 30-35. doi:10.1111/j.1365-2516.2006.01258.x Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/23717
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Ethical issues in haemophilia
Abstract
Ethical issues surrounding both the lack of global access to care as well as the implementation of advancing technologies, continue to challenge the international haemophilia community. Haemophilia is not given the priority it deserves in most developing countries. Given the heavy burdens of sickness and disease and severe resource constraints, it may not be possible to provide effective treatment to all who suffer from the various 'orphan' diseases. Nevertheless, through joint efforts, some package of effective interventions can be deployed for a significant number of those who are afflicted with 'orphan' diseases. With cost-effective utilization of limited resources, a national standard of care is possible and affordable. Gene-based diagnosis carries attendant ethical concerns whether for clinical testing or for research purposes, even as the list of its potential benefits to the haemophilia community grows rapidly. As large-scale genetic sequencing becomes quicker and cheaper, moving from the research to the clinic, we will face decisions about the implementation of prenatal, neonatal and other screening programs. Such debates will require input from not just the health care professionals but from all stakeholders in the haemophilia community. Finally, long-term therapeutic success gene transfer in small and large animal models raises the question of when and in which patient population the novel therapeutic approach should first be studied in humans with haemophilia. Although gene therapy represents a worthy goal, the central question for the haemophilia community should be whether it wishes to volunteer itself as a model for a much broader set of innovations. © 2006 The Authors Journal compilation © 2006 Blackwell Publishing Ltd.